Oncolytic virus therapy
A method of treating a human subject with cancer is disclosed. A pharmaceutical composition is administered to the subject, the pharmaceutical composition comprising human leukocytes and a replication-competent oncolytic virus in suspension in a physiologically acceptable solution. Alternatively the pharmaceutical composition comprises human leukocytes or platelets infected with an oncolytic virus.
1. A method of treating a human subject with cancer; comprising administering to the subject an amount of a pharmaceutical composition effective to treat the subject, the pharmaceutical composition comprising human leukocytes and a replication-competent oncolytic virus in suspension in a physiologically acceptable solution, wherein
the virus binds specifically to the leukocytes; and
the ratio of plaque-forming units of the virus to number of leukocytes in the composition is at least 1:100, and
the leukocytes comprise one or both of neutrophils and lymphocytes, thereby treating the subject.
2. The method of claim 1 , wherein the leukocytes are leukocytes of the subject.
3. The method of claim 1 , wherein the leukocytes are leukocytes of a donor other than the subject.
4. The method of claim 1 , wherein the leukocytes are cultured.
5. The method of claim 1 , wherein the leukocytes are leukocytes isolated by leukopheresis.
6. The method of claim 1 , wherein the leukocytes are neutrophils.
7. The method of claim 1 , wherein the leukocytes are lymphocytes.
8. The method of claim 7 , wherein the lymphocytes are tumor-infiltrating lymphocytes.
9. The method of claim 1 , wherein the virus is a clonal virus.
10. The method of claim 1 , wherein the virus is selected from the group consisting of a Newcastle Disease Virus, a Mumps Virus, a Measles Virus, a Vesicular Stomatitis Virus, a Para-influenza Virus, an Influenza Virus, an Adenovirus, a Herpes I Virus, a Vaccinia Virus, and a Reovirus.
11. The method of claim 10 , wherein the virus is a Newcastle Disease Virus.
12. The method of claim 11 , wherein the virus is a Newcastle Disease Virus of moderate virulence.
13. The method of claim 1 , wherein the composition is administered intravenously.
14. The method of claim 1 , wherein the composition is administered intratumorally.
15. The method of claim 1 , wherein the composition is administered intraperitoneally.